Literature DB >> 33325398

Neuropathological and Biomarker Findings in Parkinson's Disease and Alzheimer's Disease: From Protein Aggregates to Synaptic Dysfunction.

Yaroslau Compta1,2, Tamas Revesz3,4,5.   

Abstract

There is mounting evidence that Parkinson's disease (PD) and Alzheimer's disease (AD) share neuropathological hallmarks, while similar types of biomarkers are being applied to both. In this review we aimed to explore similarities and differences between PD and AD at both the neuropathology and the biomarker levels, specifically focusing on protein aggregates and synapse dysfunction. Thus, amyloid-β peptide (Aβ) and tau lesions of the Alzheimer-type are common in PD and α-synuclein Lewy-type aggregates are frequent findings in AD. Modern neuropathological techniques adding to routine immunohistochemistry might take further our knowledge of these diseases beyond protein aggregates and down to their presynaptic and postsynaptic terminals, with potential mechanistic and even future therapeutic implications. Translation of neuropathological discoveries to the clinic remains challenging. Cerebrospinal fluid (CSF) and positron emission tomography (PET) markers of Aβ and tau have been shown to be reliable for AD diagnosis. Conversely, CSF markers of α-synuclein have not been that consistent. In terms of PET markers, there is no PET probe available for α-synuclein yet, while the AD PET markers range from consistent evidence of their specificity (amyloid imaging) to greater uncertainty of their reliability due to off-target binding (tau imaging). CSF synaptic markers are attractive, still needing more evidence, which currently suggests those might be non-specific markers of disease progression. It can be summarized that there is neuropathological evidence that protein aggregates of AD and PD are present both at the soma and the synapse. Thus, a number of CSF and PET biomarkers beyond α-synuclein, tau and Aβ might capture these different faces of protein-related neurodegeneration. It remains to be seen what the longitudinal outcomes and the potential value as surrogate markers of these biomarkers are.

Entities:  

Keywords:  Parkinson’s disease; alzheimer’s disease; amyloid-β; biomarkers; cerebrospinal fluid; lewy-type pathology; molecular imaging; synaptic dysfunction; tau; α-Synuclein

Year:  2021        PMID: 33325398     DOI: 10.3233/JPD-202323

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  12 in total

Review 1.  The penalty of stress - Epichaperomes negatively reshaping the brain in neurodegenerative disorders.

Authors:  Stephen D Ginsberg; Suhasini Joshi; Sahil Sharma; Gianny Guzman; Tai Wang; Ottavio Arancio; Gabriela Chiosis
Journal:  J Neurochem       Date:  2021-10-31       Impact factor: 5.372

2.  Application of α-Syn Real-Time Quaking-Induced Conversion for Brain and Skin Specimens of the Chinese Patients With Parkinson's Disease.

Authors:  Dong-Dong Chen; Ling Jiao; Yue Huang; Kang Xiao; Li-Ping Gao; Cao Chen; Qi Shi; Xiao-Ping Dong
Journal:  Front Aging Neurosci       Date:  2022-07-01       Impact factor: 5.702

3.  A Novel Way of Measuring Dual-Task Interference: The Reliability and Construct Validity of the Dual-Task Effect Battery in Neurodegenerative Disease.

Authors:  Jason K Longhurst; John V Rider; Jeffrey L Cummings; Samantha E John; Brach Poston; Elissa C Held Bradford; Merrill R Landers
Journal:  Neurorehabil Neural Repair       Date:  2022-04-06       Impact factor: 4.895

4.  A Quantitative Model of Sporadic Axonal Degeneration in the Drosophila Visual System.

Authors:  Mélisande Richard; Karolína Doubková; Yohei Nitta; Hiroki Kawai; Atsushi Sugie; Gaia Tavosanis
Journal:  J Neurosci       Date:  2022-05-09       Impact factor: 6.709

5.  Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders.

Authors:  Luisa Agnello; Bruna Lo Sasso; Matteo Vidali; Concetta Scazzone; Caterina Maria Gambino; Tommaso Piccoli; Giulia Bivona; Anna Maria Ciaccio; Rosaria Vincenza Giglio; Vincenzo La Bella; Marcello Ciaccio
Journal:  J Clin Med       Date:  2022-05-31       Impact factor: 4.964

Review 6.  Modelling the functional genomics of Parkinson's disease in Caenorhabditis elegans: LRRK2 and beyond.

Authors:  Rachael J Chandler; Susanna Cogo; Patrick A Lewis; Eva Kevei
Journal:  Biosci Rep       Date:  2021-09-30       Impact factor: 3.840

Review 7.  Mitochondrial Dysfunction, Protein Misfolding and Neuroinflammation in Parkinson's Disease: Roads to Biomarker Discovery.

Authors:  Anna Picca; Flora Guerra; Riccardo Calvani; Roberta Romano; Hélio José Coelho-Júnior; Cecilia Bucci; Emanuele Marzetti
Journal:  Biomolecules       Date:  2021-10-13

8.  Glutamatergic Synapse Dysfunction in Drosophila Neuromuscular Junctions Can Be Rescued by Proteostasis Modulation.

Authors:  Anushka Chakravorty; Ankit Sharma; Vasu Sheeba; Ravi Manjithaya
Journal:  Front Mol Neurosci       Date:  2022-07-15       Impact factor: 6.261

Review 9.  Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson's disease.

Authors:  Nouara Yahi; Coralie Di Scala; Henri Chahinian; Jacques Fantini
Journal:  Glycoconj J       Date:  2021-07-30       Impact factor: 2.916

Review 10.  News about the Role of Fluid and Imaging Biomarkers in Neurodegenerative Diseases.

Authors:  Jacopo Meldolesi
Journal:  Biomedicines       Date:  2021-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.